Allogene Therapeutics, Inc.

ALLO Nasdaq SEC CIK 1737287
Follow Allogene Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$50.4M −21.7% vs same quarter last year
EPS, diluted −$0.15 +21.1% vs same quarter last year
Operating cash flow −$36.1M −21.7% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$4.6M
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$190.9M
FY24$22K−$257.6M
FY23$95K−$327.3M
FY22$156K−$340.4M
FY21$114.1M−$182.1M
FY20$0−$316.4M
FY19$0−$184.6M
FY18-−$211.5M
FY17--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1500000%−1000000%−500000%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24−1241813.6%−1170863.6%
FY23−344986.3%−344489.5%
FY22−215087.2%−218214.1%
FY21−157.9%−159.6%
FY20--
FY19--
FY18--
FY17--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$149.6M
FY24−$201M
FY23−$239.2M
FY22−$225.7M
FY21−$206.3M
FY20−$181.1M
FY19−$188.1M
FY18−$47.9M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Allogene Therapeutics
  • Healthcare median
−1500000%−1000000%−500000%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearAllogene TherapeuticsHealthcare median
FY25-−30.6%
FY24−1170863.6%−47%
FY23−344489.5%−58%
FY22−218214.1%−80.4%
FY21−159.6%−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%